Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer
December 14 2020 - 07:00AM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
biotechnology company developing novel T cell-based cancer
immunotherapies, today announced the appointment of Jean-Marc
Bellemin as Chief Financial Officer, effective today. Mr. Bellemin
brings 27 years of industry experience in finance, including public
companies.
“I am very pleased to welcome Jean-Marc to Iovance during such
an important time for the Company,” stated Maria Fardis, Ph.D.,
President and Chief Executive Officer of Iovance Biotherapeutics.
“Jean-Marc has extensive experience as a CFO in public biopharma
companies with commercial products and with a global footprint, as
well as an understanding of cell therapy products. His
qualifications are well aligned with Iovance’s goals and
directions.”
Mr. Bellemin has 27 years of progressive international
experience in finance, business leadership and operations
management within start-up and global multi-billion-dollar
organizations. Most recently he served as Executive Vice President
and Chief Financial Officer of Gritstone Oncology, where he led the
overall financial strategy and multiple private and public
financings, including an initial public offering and first equity
follow-on financing. Previously Mr. Bellemin held roles of
increasing responsibility at Actelion Pharmaceuticals, from 2002
until the 2017 acquisition by Johnson & Johnson. As Senior Vice
President and Chief Financial Officer, Head of Finance and Market
Access at Actelion Pharmaceuticals US Inc., he provided strategic
leadership, operations, and financial management. Mr. Bellemin was
actively involved in the launch of six drugs within five years,
including three ‘blockbusters’ drugs, helping drive Actelion US to
$1.8 billion in revenue.
“I am very excited to join Iovance and help lead the important
transition toward bringing TIL to patients in a commercial
setting,” said Mr. Bellemin. “I believe TIL cell therapy is a true
platform with the potential to address many thousands of cancer
patients in multiple indications throughout the world. I look
forward to offering my expertise in global finance and commercial
operations to help create value for patients and physicians, as
well as Iovance shareholders.”
About Iovance Biotherapeutics, Inc.Iovance
Biotherapeutics aims to improve patient care by making T cell-based
immunotherapies broadly accessible for the treatment of patients
with solid tumors and blood cancers. Tumor infiltrating lymphocyte
(TIL) therapy uses a patient’s own immune cells to attack cancer.
TIL cells are extracted from a patient’s own tumor tissue, expanded
through a proprietary process, and infused back into the patient.
Upon infusion, TIL reach tumor tissue, where they attack cancer
cells. The company has completed dosing in the pivotal study in
patients with metastatic melanoma and cervical. In addition, the
company’s TIL therapy is being investigated for the treatment of
patients with locally advanced, recurrent or metastatic cancers
including head and neck and non-small cell lung cancer. A clinical
study to investigate Iovance T cell therapy for blood cancers
called peripheral blood lymphocyte (PBL) therapy is open to
enrollment. For more information, please visit www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are
“forward-looking statements” of Iovance Biotherapeutics, Inc.
(hereinafter referred to as the “Company,” “we,” “us,” or “our”)
within the meaning of the Private Securities Litigation Reform Act
of 1995 (the “PSLRA”). All such written or oral statements made in
this press release, other than statements of historical fact, are
forward-looking statements and are intended to be covered by the
safe harbor for forward-looking statements provided by the PSLRA.
Without limiting the foregoing, we may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,”
“forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes and are intended to identify forward-looking statements.
Forward-looking statements are based on assumptions and assessments
made in light of management’s experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and we undertake no duty to update or revise any
such statements, whether as a result of new information, future
events or otherwise. Forward-looking statements are not guarantees
of future performance and are subject to risks, uncertainties and
other factors, many of which are outside of our control, that may
cause actual results, levels of activity, performance, achievements
and developments to be materially different from those expressed in
or implied by these forward-looking statements. Important factors
that could cause actual results, developments and business
decisions to differ materially from forward-looking statements are
described in the sections titled “Risk Factors“ in our filings with
the Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and
include, but are not limited to, the following substantial known
and unknown risks and uncertainties inherent in our business: the
effects of the COVID-19 pandemic; risks related to the timing of
and our ability to successfully develop, submit, obtain and
maintain U.S. Food and Drug Administration (“FDA”) or other
regulatory authority approval of, or other action with respect to,
our product candidates, and our ability to successfully
commercialize any product candidates for which we obtain FDA
approval; preliminary and interim clinical results, which may
include efficacy and safety results, from ongoing clinical trials
may not be reflected in the final analyses of our ongoing clinical
trials or subgroups within these trials; the risk that enrollment
may need to be adjusted for our trials and cohorts within those
trials based on FDA and other regulatory agency input; the new
version of the protocol which further defines the patient
population to include more advanced patients in our cervical cancer
trial may have an adverse effect on the results reported to date;
the risk that we may be required to conduct additional clinical
trials or modify ongoing or future clinical trials based on
feedback from the FDA or other regulatory authorities; the risk
that our interpretation of the results of our clinical trials or
communications with the FDA may differ from the interpretation of
such results or communications by the FDA; the acceptance by the
market of our product candidates and their potential reimbursement
by payors, if approved; our ability or inability to manufacture our
therapies using third party manufacturers or our own facility may
adversely affect our potential commercial launch; the results of
clinical trials with collaborators using different manufacturing
processes may not be reflected in our sponsored trials; the risk
that unanticipated expenses may decrease our estimated cash
balances and increase our estimated capital requirements; and other
factors, including general economic conditions and regulatory
developments, not within our control.
CONTACTS
Iovance Biotherapeutics, Inc:Sara Pellegrino,
IRCVice President, Investor Relations & Public
Relations650-260-7120 ext. 264Sara.Pellegrino@iovance.com
Solebury Trout:Chad Rubin
(investors)646-378-2947crubin@troutgroup.com
Rich Allan (media)646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2023 to Mar 2024